Severe obstetric complications, including preeclampsia, intrauterine growth retardation, abruptio placentae, and stillbirth, constitute a major cause of maternal and perinatal morbidity and death. The etiology of these severe obstetric complications is still unknown. However, the frequent finding of structural and thrombotic changes in placental capillaries, which lead to inadequate fetomaternal circulation and decreased placental perfusion, and the high prevalence of heritable or acquired risk factors for thrombosis found in women with these complications strongly suggest a cause-and-effect relationship. This review describes the recent findings on the association between these obstetric complications and the various thrombophilias, and recent therapeutic approaches. Aspirin, which was regarded as the drug of choice for the prevention of such obstetric complications, has proved to be ineffective in a large clinical trial. The encouraging observations on the efficacy of low-molecular-weight heparins, which are also included in the recently published guidelines of The American College of Chest Physicians, are summarized in this review. However, controlled clinical trials are still necessary to allow the development of better clinical standards.
and the high prevalence of thrombophilias strongly suggest a cause-and-effect relationship.
The etiology of these severe obstetric complications is still unknown and their cause is multifactorial. A certain familial predisposition has been described, which suggests some genetic predisposition. 6 Endothelial dysfunction, vasoconstriction, placental ischemia, and inflammation are frequent findings. [1] [2] [3] [4] [5] [6] [7] The pathologic features of preeclampsia include thrombosis of the spiral arteries, which impairs placental perfusion. IUGR is associated with villous infarctions, avascular villi, atheromatosis, and thrombosis of uteroplacental vessels. [1] [2] [3] [4] [5] [6] [7] Severe abruptio placentae is found in about 50% of pregnancies that result in low-birth-weight infants, and stillbirth is also related to impaired placental development and compromised uteroplacental vessels. In normal pregnancy, the trophoblast invades the spiral arteries, which lose their muscular wall and become flaccid, allowing sufficient blood flow to the placenta. In women with obstetric complications, an abnormal trophoblastic invasion of the spiral arteries occurs and small narrowed spiral arteries are found. [1] [2] [3] [4] [5] [6] [7] This vasculopathy and the associated thrombosis lead to inadequate perfusion of the intervillous spaces and are facilitated by the physiological hypercoagulability of pregnancy, which may be enhanced in women with congenital or acquired thrombophilias.
Several inherited molecular risk factors for venous thromboembolism (VTE) are now recognized. 8, 9 Deficiencies in the natural coagulation inhibitors protein C, protein S, and antithrombin, as well as elevated levels of coagulation factors (F) VIII, IX, and XI, predispose patients to thromboembolic events. 8, 10, 11 Mutations in coagulation factors increase the risk of venous thrombosis and appear to have a high prevalence in the general population. 8, 9 These include the FV gene mutation G1691A coding for factor V Leiden, which is associated with resistance to activated protein C, 12 and the prothrombin gene mutation G20210A, associated with elevated plasma FII levels. 13 Mild hyperhomocysteinemia, frequently associated with homozygosity for a common mutation (C677T) in the enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR), enhances the risk of both arterial and venous thrombosis. 14 Polymorphisms in the plasminogen activator inhibitor-1 (PAI-1) gene, especially the 4G/4G phenotype, are associated with higher plasma levels of PAI-1 and an increased risk of venous and arterial thromboembolism. 15, 16 Similarly, acquired antiphospholipid antibodies (APLA) constitute a risk factor for both venous and arterial thrombosis and obstetric complications. 17 The risk of thrombosis in pregnant women may be further amplified by the type of underlying genetic predisposition; for example, homozygosity for a mutation, the presence of multiple mutations (multigenic defects), or thrombophilic anomalies. 18 It is now clear that not all thrombophilias are associated with the same level of thrombotic risk.
HYPERCOAGULABILITY OF NORMAL PREGNANCY
Normal pregnancy is associated with acquired changes in hemostatic factors that contribute to the hypercoagulable state. These include elevations of the plasma levels of fibrinogen and FVIII, acquired functional resistance to activated protein C, a decrease in protein S, increases in PAI-1 and PAI-2, and platelet activation. 19, 20 Pregnancy is an independent risk factor for the development of VTE and this risk is increased by the presence of thrombophilia. Not all women with thrombophilia will develop VTE or obstetric complications during pregnancy, and this suggests the existence of additional, yet unidentified, environmental factors. 21 
HEREDITARY THROMBOPHILIAS AND PREGNANCY
Antithrombin deficiency is the most thrombogenic of the hereditary thrombophilias, with a 50% chance of thrombosis throughout the patient's lifetime. 22 The frequency of antithrombin deficiency in the general population is 0.02 to 0.17% and is higher in patients with VTE (1.1%). The risk of thromboembolism in antithrombin-deficient pregnant women not receiving anticoagulant therapy is about 50%. 10, 11 Abnormalities of the protein C and protein S system are present in 0.14 to 0.5% of the general population and 3.2% of patients with thrombosis. The risk of thrombosis in pregnancy is 3 to 10% for protein C deficiency and 0 to 6% for protein S deficiency, and in postpartum women, the thrombosis risk is 7 to 19% for protein C deficiency and 7 to 22% for protein S deficiency. 11, 20, 23 During pregnancy there is a marked decrease in protein S levels (free protein S) in 25% of healthy women in the first trimester, 60% in the second trimester, and 83 to 100% in the third trimester. 24 Activated protein C resistance (APCR) is present in 3 to 7% of healthy Caucasians and in 20 to 30% of patients with thrombosis. 20 In the majority of these patients, APCR is caused by factor V Leiden. APCR has been found in up to 78% of women investigated for venous thrombosis in pregnancy, whereas the factor V Leiden genotype was found in up to 46%. 25, 26 APCR can be caused by disorders other than factor V Leiden, including APLS or other genetic defects in the FV molecule. 20 The resistance can also be acquired during the second and third trimester of normal pregnancy as a result of increased FV and FVIII levels, and decreased levels of protein S. 27 The precise mechanism for this physiological APCR and its contribution to the higher risk of VTE during pregnancy are still not known.
The prothrombin G20210A gene mutation is associated with elevated plasma prothrombin levels (FII activity > 130%) and is present in about 2 to 5% of healthy individuals. 13 This mutation has been associated with a 3-fold increased risk of VTE. 8, 13 This risk was further increased in women using oral contraceptives 28 and in women with obstetric complications. 29 Hyperhomocysteinemia is frequently associated with homozygosity for the thermolabile variant of MTHFR (C677T) 1 and is present in about 8 to 10% of healthy individuals. 14, 30 Pregnancy is associated with decreased concentrations of homocysteine, and folic acid supplements will also lower homocysteine concentrations. The contribution of homocysteine to VTE in pregnancy remains unclear, however. McColl et al 31 revealed that homozygosity for the C677T MTHFR mutation was not associated with an increase in risk for VTE during pregnancy. This may be because plasma homocysteine concentrations decrease during pregnancy and most pregnant women take folic acid supplements, which ameliorate hyperhomocysteinemia. 21 Interestingly, inherited thrombophilias may have positive aspects during pregnancy. For example, the factor V Leiden mutation has been associated with a reduced risk of intrapartum bleeding complications, conferring a possible survival advantage for carriers. 32 THROMBOPHILIA AND SEVERE OBSTETRIC COMPLICATIONS Kupferminc et al 29 compared 110 women who had severe preeclampsia, IUGR, abruptio placentae, or stillbirth with 110 women who had successfully completed one or more normal pregnancies. At least one of the factor V Leiden mutations, the prothrombin G20210A gene mutation and the homozygous MTHFR mutation, was detected in each of 57 women with obstetric complications (52%) and 19 women in the control group (17%; p < 0.001). Deficiencies in protein S, protein C, antithrombin, or anticardiolipin antibodies were detected in an additional 14 women with obstetric complications compared with 1 woman in the control group. The DNA samples of these women were also analyzed for the 4G/ 4G polymorphisms of PAI-1, which confer an increased risk for thrombosis. Women with obstetric complications were significantly more likely (32%, 30 of 94) than controls (19%, 18 of 95) to be homozygotes for the PAI-1 4G/4G polymorphism (odds ratio [OR], 2; 95% confidence interval [CI], 1.02 to 3.9; p = 0.041). 33 Heterozygosity or homozygosity for factor V Leiden was more common in the 30 patients who had PAI-1 4G/ 4G (33%) than in the 18 controls (0%; p = 0.006). Enhanced PAI-1 activity is an independent risk factor for the high miscarriage rate in women with polycystic ovary syndrome. 15 The role of hyperhomocysteinemia (with and without the MTHFR mutation) in pregnancy complications has also been investigated. Hyperhomocysteinemia was documented in 26% of women with abruptio placentae, 11% of women with intrauterine fetal death (IUFD), and 38% of women delivering low-birth-weight infants. 34 In another study, hyperhomocysteinemia was found in 26 of 84 (31%) women with previous placental infarcts or abruption compared with 4 of 46 (9%) control cases. 35 The Hordaland Homocysteine Study evaluated plasma homocysteine levels in 5883 women with 14,492 gestations. High levels of homocysteine were found to be related to an increased risk for preeclampsia, stillbirth, early labor, and abruptio placentae (OR 1.33, 2.11, 1.41, and 3.03, respectively). 36 Van der Molen et al 37 studied 101 women with an obstetric history of placental vasculopathy, whom they compared with 92 nonpregnant women. In the study group, the OR for elevated plasma homocysteine levels was 2.28 (95% CI, 1.18 to 4.39), for the MTHFR mutation the ratio was 3.29 (95% CI, 1.03 to 10.5), for decreased APCR the ratio was 2.46 (95% CI 1.06 to 5.72), and for decreased protein C the ratio was 2.01 (95% CI, 1.11 to 3.65). Any combination of two risk factors in the same individual resulted in a 3.40 (95% CI, 1.80 to 6.42) higher relative risk for placental vasculopathy, whereas combinations of three risk factors resulted in a 6.83 (95% CI, 1.52 to 30.7) higher relative risk.
The association between thrombophilia and pregnancy complications was strongly suggested using another experimental approach. Pabinger et al 38 investigated whether women with a history of VTE have a higher prevalence of pregnancy complications compared with controls who have not experienced any thrombotic event. They found that the prevalence of pregnancy-induced hypertension and/or preeclampsia was 7.6% among 395 patients with previous VTE, compared with 2.6% in 313 controls (OR, 3.1; 95% CI, 1.4 to 7.0; p = 0.003), indicating that predisposition to venous thrombosis is associated with complications during pregnancy.
Interestingly, recent analysis of placental DNA has shown an association between thrombophilia, especially factor V Leiden, and thromboembolic events in the fetus, which include congenital stroke and renal-vein thromboses. 39 
Thrombophilia and Severe Preeclampsia
Several studies have investigated the association between thrombophilias and preeclampsia. Dekker et al 40 studied women with severe preeclampsia and found that 24.7% had protein S deficiency, 16% had APCR, 17.7% had hyperhomocysteinemia, and 29.4% had anticardiolipin antibodies, either immunoglobulin G (IgG) or IgM. There is also a high prevalence of factor V Leiden in women with preeclampsia compared with controls. [41] [42] [43] Rajkovic et al 44 reported that homocysteine levels were elevated in 20 women with preeclampsia compared with 20 healthy controls, whereas the levels of folic acid and vitamin B12 were similar between the two groups. A significant increase in homozygosity for the C677T MTHFR mutation in preeclampsia has been reported. 42 , 45 Sohda et al 45 studied 67 women with mild preeclampsia and 98 healthy pregnant women and found a 24% prevalence in women with preeclampsia compared with 11% in controls.
Our group recently performed a case-control study in women with severe preeclampsia. Thrombophilia was found in 56% (35 of 63) of patients compared with 19% (24 of 126) of healthy women (p < 0.001); women with thrombophilia delivered at an earlier gestational age, and their neonates had lower birth weights than those of women without thrombophilia. 46 The prevalence of factor V Leiden was significantly increased, as was reported in other studies. 25, 26 The prevalence of the prothrombin gene mutation in study women was more than double that in normal women (8% versus 3%), but this did not reach statistical significance. 46 However, more than 200 women are needed in each group before the statistical power is sufficient to conclude that this mutation is not more prevalent in severe preeclampsia.
Rigo et al 47 investigated 120 women with severe preeclampsia and 101 matched, healthy women. Of the women with preeclampsia, 18.3% were carriers of factor V Leiden, compared with 3% of controls (p < 0.001), and the women with factor V Leiden had a significantly higher incidence of the hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. There were no differences in the prevalence of homozygous MTHFR mutation.
Mello et al 48 investigated 46 women with preeclampsia and 34 women with a history of fetal loss in the second and third trimester. The prevalence of APCR and factor V Leiden was significantly higher in women with preeclampsia (26.1%) or a history of fetal loss (23%) compared with the control group (3.8%). The prevalence of any one thrombophilia was 37% in women with previous preeclampsia, 41.2% with previous fetal loss, and 7.5% in the control group. 48 In several studies, no association was found between inherited thrombophilia and preeclampsia. Lindoff et al 49 compared 50 women with preeclampsia with 50 controls. The APCR ratios were significantly lower in women with preeclampsia but the difference in factor V mutation was not significant. O'Shaughnessy et al 50 prospectively compared 283 women with preeclampsia with 200 age-matched healthy women. There were no differences in the frequency of factor V Leiden or MTHFR mutation. Powers et al 51 found no differences in the prevalence of MTHFR mutation between 99 nulliparous women with preeclampsia, 24 women with transient hypertension of pregnancy, and 114 control women. Krauss et al 52 found a higher incidence of APCR in 21 women with the HELLP syndrome than in 70 healthy nonpregnant women. Four of these women with a higher incidence of APCR and HELLP had factor V Leiden, one woman had protein S deficiency, and one woman had protein C deficiency. Lindqvist et al 53 investigated 2480 pregnant women and found an 11% prevalence of APCR. The subgroup of women with APCR (n = 270) did not differ significantly from the non-APCR group (n = 2210) in terms of the incidence of pregnancy complications, but was characterized by an 8-fold higher risk of VTE (3 of 270 versus 3 of 2210 women), a lower rate of profuse intrapartum hemorrhage, and less intrapartum blood loss.
The difference in the studies that found association between preeclampsia and thrombophilias and those that did not find such an association may be related to the different populations studied, the particular study design, and the definition of the severity of preeclampsia. Factor V Leiden is present mainly in Caucasian populations, and there are differences in the incidence ranging from 10 to 15% in Sweden to 4 to 8% in central Europe and 2% in southern Europe. 18 Preeclampsia is a multifactorial disease and there are significant differences in prognosis and management between early-onset severe preeclampsia and late, mild disease. The association of low-pressure intervillous blood flow with thrombophilia may facilitate fibrin deposition, causing placental infarcts that may lead to the development of early severe disease. This assumption is supported by the observation that women with preeclampsia and thrombophilia have higher rates of fetal growth retardation and deliver at an earlier gestational age, compared with women with preeclampsia and no thrombophilia. 54 
Thrombophilia and Pregnancy Loss
Recurrent pregnancy loss (RPL) is a common health problem affecting 1 to 2% of women of reproductive age. APLS is commonly associated with RPL, and with the presence of placental infarctions and thrombotic changes in decidual microvessels. 17, 55, 56 Hereditary thrombophilias are associated with RPL and also with second trimester abortion. [57] [58] [59] Brenner et al 60, 61 examined a group of 76 women with RPL of no apparent cause. Significantly more women with RPL had some form of thrombophilia (49%) compared with the control group (21%). 60 In particular, factor V Leiden was significantly more common in the RPL group. 61 A large European study 62 (the European Prospective Cohort on Thrombophilia [EPCOT]) analyzed the risk of fetal loss in a cohort of 571 women with a variety of known inherited thrombophilias. The study described ORs of 3.6 for stillbirth and 1.3 for miscarriage. 62 Women with factor V Leiden had ORs of 2.0 for stillbirth and 0.9 for miscarriage.
Various other studies have examined the incidence of RPL in women with thrombophilia. A casecontrol study of 60 women with documented thrombophilias revealed an increased risk of RPL. 63 Ridker et al 64 reported a 2.3-fold increased prevalence of factor V Leiden in women with RPL.
Several studies have evaluated the potential role of the prothrombin G20210A gene mutation in RPL. A study by Martinelli et al 28 showed that both factor V Lei-den and the prothrombin mutation are associated with an approximate tripling of the risk of late fetal loss. Another study demonstrated an OR of 2.2 (95% CI, 0.6 to 8.0; p = 0.23) for prothrombin G20210A in the RPL group compared with controls. 60 Other studies have demonstrated no difference in the prevalence of the prothrombin mutation between women with RPL and controls. 65, 66 One study found a significant risk associated with the MTHFR mutation but not with the prothrombin G20210A gene mutation or factor V Leiden. 66 A high prevalence of FXII deficiency (2.9%) was also found among 241 women with a history of recurrent miscarriage. 67 
Thrombophilia and Abruptio Placentae
Van der Molen et al 37 compared 101 nonpregnant women with a history of placental vasculopathy defined as abruption or placental infarctions, with 92 nonpregnant women matched for age and occupation. 37 Placental infarction was defined as villous necrosis combined with stillbirth or IUGR of less than the 10th percentile. Twenty-two of the 101 investigated women also had hypertension during pregnancy. Protein C activity was significantly lower in the study group, and there were significantly more homozygotes for the MTHFR mutation and carriers of factor V Leiden in the study group. The median homocysteine levels, APCR ratios, and protein S and antithrombin levels were not different between the groups. However, a homocysteine level above 14.4 µM/L, which was the 80th percentile of the controls, was associated with a significant increased risk for placental vasculopathy. In addition, a combination of risk factors such as high homocysteine and low protein S levels resulted in significant relative risks.
Wiener-Megnagi et al 68 studied 27 women who had abruptio placentae and 29 control women matched for age, parity, and ethnic origin. Of the patients, 63% had a low APCR ratio (Յ 2.5), compared with 17% of the control subjects (p = 0.00125). Participants with an APCR ratio of 2.5 or less underwent DNA analysis; 8 of the 15 patients tested were found to have factor V Leiden (5 heterozygous and 3 homozygous), compared with 1 heterozygote found among the control group.
Goddijn-Wessel et al 35 found hyperhomocysteinemia in 31% of women with abruptio placentae compared with 9% of controls (p < 0.05). Kupferminc et al 29 found a 70% incidence of thrombophilias in women with abruptio placentae; 60% had thrombophilic mutations and 10% had antithrombin deficiency or APLA. Of the 20 women with abruptio placentae, 3 had mild preeclampsia and 7 had antepartum or postpartum hypertension. Eleven of the neonates were below the 10th percentile for gestational age.In this study, the OR for the prothrombin mutation was 8.9 (95% CI, 1.8 to 43.6), for factor V Leiden the OR was 4.9 (95% CI, 1 to 17.4), and for the homozygous MTHFR mutation the OR was 2 (95% CI, 0.5 to 8.1).
Thrombophilia and IUGR
Only a few studies have reported an association between IUGR and thrombophilia. de Vries et al 34 studied thrombophilias in 62 women with obstetric complications but without a control group. Thirty-one women had abruptio placentae, 18 had IUFD, and 13 had IUGR. The women with IUGR had a high incidence of hyperhomocysteinemia (38%), protein S deficiency (23%), and factor V Leiden (12.5%). In the study of Kupferminc et al 29 described earlier,women with severe IUGR had a higher prevalence of homozygosity for the MTHFR and prothrombin mutations. The prevalence of factor V Leiden in the study group was twice that in the control group, but this difference was not significant. The prevalence of all thrombophilias in women with IUGR was 61.4%.
Recently, Kupferminc et al 69 investigated the prothrombin mutation in 222 patients with severe preeclampsia (n = 55), mild preeclampsia (n = 25), IUGR defined as birth weight below the 10th percentile (n = 72), severe abruptio placentae (n = 27), unexplained stillbirth at more than 23 weeks gestation (n = 16), second trimester fetal loss, and three or more consecutive first trimester losses. The control group consisted of 156 healthy women who had had at least one normal pregnancy. In the study group, 28 (13%) women were found to be heterozygous carriers of the prothrombin mutation compared with 5 (3.2%) in the control group (OR, 2.9; 95% CI, 1.3 to 6.5; p = 0.001). The prothrombin gene mutation was significantly more prevalent in women with IUGR, abruptio placentae, and second trimester loss than in the control group, but not in women with mild or severe preeclampsia, stillbirth, and habitual abortion. The 28 women in the study group who were carriers of the prothrombin mutation had 62 pregnancies of which only 7 (11.3%) were normal. Fourteen of these women had previous pregnancies. Of 9 carriers of the mutation who had had previous pregnancies and who carried their pregnancies beyond the first trimester, 6 (66%) had experienced some obstetric complications in the previous pregnancy. In comparison, such complications occurred in 27 of 112 (24%) multiparous women in the study group without the mutation (p = 0.01).
PLACENTAL PATHOLOGY ASSOCIATED WITH THROMBOPHILIA AND PREGNANCY COMPLICATIONS
Arias et al 70 investigated 13 women who were found to have thrombotic lesions of the placenta. All had obstetric complications including preeclampsia, preterm labor, IUGR, or stillbirth. Of the 10 women (77%) found to have thrombophilia, 7 were heterozygous for factor V Leiden and 3 had protein S deficiency. The most prominent placental lesions were hypoplasia, multiple infarcts, thrombosis of fetal stem vessels, spiral artery thrombosis, and perivillous fibrin deposition.
Kupferminc et al 71 systematically studied the placentas of women with thrombophilia who had severe obstetric complications and compared them to placentas of women with severe obstetric complications and no detectable thrombophilia. The study population comprised 68 women with singleton pregnancies who had severe preeclampsia, IUGR, abruptio placentae, or IUFD. They were investigated after delivery for factor V Leiden, the MTHFR and prothrombin mutations, and deficiencies in protein S, protein C, and antithrombin. All were negative for APLA, but 32 were found to have thrombophilia. All of the placentas were evaluated by a pathologist who was blinded to the thrombophilia results. There was no difference in the maternal age, parity, type of pregnancy complication, and fetoplacental weight ratio between the groups. The gestational age at delivery, birth weight, and placental weight were significantly lower in the 32 women with thrombophilias compared with the 36 women without thrombophilias. The number of placentas with villous infarcts was significantly higher in women with thrombophilias (72%) than in those without thrombophilias (39%; p < 0.001), as were the number of placentas with multiple infarcts (p < 0.05) and the number of placentas with fibrinoid necrosis of decidual vessels (p < 0.05). Another study with a similar design, which examined the relationship between placental pathology and thrombophilia in women with severe obstetric complications, failed to detect any specific histologic pattern that could discriminate between women with and without thrombophilia. 72 
MANAGEMENT OF THROMBOPHILIA ASSOCIATED WITH OBSTETRIC COMPLICATIONS
Women with a history of obstetric complications were commonly treated with low-dose aspirin throughout a subsequent pregnancy until a large multicenter study revealed that aspirin did not reduce the incidence of preeclampsia or improve perinatal outcomes. 73 Alternative or additional antithrombotic drugs may therefore be indicated in the management of preeclampsia. In this context, the findings of studies investigating the role of aspirin and heparin in women with APLA could be extrapolated. The addition of heparin to aspirin resulted in a successful outcome in 83 of 93 gestations in women with RPL, and in all 28 gestations in women who had experienced preeclampsia during a previous pregnancy. 74 Unfractionated heparin (UFH) used to be the antithrombotic drug of choice for the prevention and treatment of thrombotic events during pregnancy. Because of its significant side effects, the administration of at least two daily injections, and the need for monitoring, it is now gradually being replaced by low-molecular-weight heparins (LMWHs). Animal and human studies have shown that LMWHs are not teratogenic or fetotoxic and do not cross the placenta. 75 Oral anticoagulants are rarely employed during pregnancy. Coumarin derivatives cross the placenta and are associated with severe side effects such as embryopathy observed during the first trimester and central nervous system hemorrhages in any trimester. 20, 76 Administration of enoxaparin, 20 mg once daily, to women with primary early RPL and an impaired fibrinolytic capacity produced positive results. 77 There was normalization of impaired fibrinolysis, conception in 16 of 20 cases (80%), and successful live birth in 13 of 16 cases (81%). Brenner et al 61, 78 reported that in women with inherited thrombophilia and RPL, the percentage of live births increased from 20% without therapy to 75% following treatment with LMWH enoxaparin. Younis et al 79 and Bar et al 80 also reported on the administration of enoxaparin in women with unexplained RPL associated with factor V Leiden or women with recurrent obstetric complications. They concluded it to be safe, allowing normal fetal development and good neonatal outcome.
The combination of aspirin and heparin or LMWH is effective in RPL in APLA syndrome, and could be considered for women with inherited thrombophilias and a history of severe preeclampsia, IUGR, abruptio placentae, or fetal loss, although no controlled studies are currently available. Kutteh et al 74 compared aspirin to aspirin and heparin for the prevention of RPL in women with APLA. Viable infants were delivered in only 44% of women receiving aspirin compared with 80% in women also receiving heparin (p < 0.05). In a study of similar design, Rai et al 81 found that the rate of live birth in patients treated with aspirin and heparin or LMWH was 71% compared with 42% with aspirin alone (p < 0.01). It should be noted that 25% of the successful pregnancies were delivered prematurely.
We have recently treated 32 thrombophilic women who had previously experienced severe complications of pregnancy. 82 Enoxaparin (40 mg once daily) and aspirin (100 mg per day) were administered from week 12 of gestation until 6 weeks postpartum. The mean gestational age (37.7 ± 4.9 versus 32.2 ± 4.9 weeks) and birth weight (2795 ± 540 versus 1123 ± 655 g) were significantly higher in the treated pregnancies than in the previous untreated pregnancies. All newborns survived with no morbidity, although complications occurred in three of the treated pregnancies. In a similar study, 26 patients with documented thrombophilia and a history of preeclampsia or IUGR were treated with nadroparin (7500 IU twice daily) and aspirin (80 mg once daily) throughout pregnancy. 83 The birth weight of babies born to these women was higher than in patients with no prothrombotic predisposition.
Hyperhomocysteinemia in pregnancy is usually managed with folate supplementation (1 mg per day). Although such an approach seems logical, there is no evidence to suggest that lowering the homocysteine concentration is beneficial for the mother or child, in terms of lowering the risk of thromboembolic complications.
Leeda et al 84 studied the effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or IUGR. Of 207 consecutive patients with a history of preeclampsia or IUGR tested for hyperhomocysteinemia, 37 were found to be positive and were treated with folic acid and vitamin B6, 27 of whom had a second methionine loading test after vitamin supplementation. Fourteen patients became pregnant again while receiving vitamins and aspirin. All patients who underwent a methionine loading test after vitamin supplementation had a completely normalized methionine loading test. Of the 14 pregnancies in women receiving vitamins and aspirin, 7 were complicated by preeclampsia. The mean birth weight was 2867 ± 648 g compared with 1088 ± 570 g in the previous pregnancies (p < 0.001). Thus, vitamin B6 and folic acid corrected the homocysteine concentration in patients with hyperhomocysteinemia. Birth weight in patients with a history of preeclampsia or IUGR and hyperhomocysteinemia appears to improve with supplementation, but the rate of preeclampsia does not improve.
The recent American College of Chest Physicians (ACCP) recommendations suggest the administration of low-dose aspirin, low-dose heparin, or prophylactic LMWH to women with thrombophilia and recurrent miscarriages, a miscarriage during or after the second trimester, or preeclampsia, IUGR, or spontaneous abortion. 85 This is a grade 2C recommendation, which is a weak recommendation that is based on observational studies and not on controlled trials. Women with APLA who have had at least two fetal losses should receive prophylactic UFH (5000 IU twice daily) or LMWH and low-dose aspirin (0.1 g per day). This management strategy is documented by well-controlled, small, prospective studies and is recommended by the ACCP (grade 1B recommendation). Treatment should start after confirmation of pregnancy and continue until 8 weeks after the delivery. Corticosteroids give no additional benefit and should be administered only to women with APLS secondary to systemic lupus erythematosus or women with APLS and severe thrombocytopenia. Intravenous infusions of gamma globulin (400 mg/kg for 5 days, once per month) have been used to improve the outcome of pregnancy in a limited number of women with APLS, although a recent controlled clinical trial demonstrated no added benefit of this treatment. 86 Women with APLA and no prior VTE or pregnancy loss should receive no therapy, or low-dose heparin, prophylactic LMWH, or low-dose aspirin (grade 2C recommendation). 85 Women with APLA and a history of VTE who are receiving longterm anticoagulation should be treated with adjusteddose LMWH or UFH throughout pregnancy and receive oral anticoagulants postpartum (grade 2C recommendation). Hyperhomocysteinemia in pregnancy or homozygous MTHFR C677T mutation should be managed with supplementary folate 1 mg per day (grade 2C recommendation). 85 
CONCLUSIONS
Evidence is accumulating to link congenital thrombophilia to several severe obstetric complications. The high prevalence of acquired or inherited thrombophilias in women presenting with recurrent miscarriages, preeclampsia, IUGR, abruptio placentae, or stillbirth has led to an effort to enhance the understanding of this relationship. Once the implications of these defects are clearly understood, appropriate assessment of therapeutic intervention can take place. However, current evidence is based only on small cohort and case-control studies, and larger randomized trials are needed to improve the therapeutic recommendations for these patients. In the meantime, women with these complications should be screened for thrombophilia and thromboprophylaxis should be considered, especially when there is a history of VTE. 
